The Life Sciences team advised SonoThera, Inc. in its $60.75 million Series A financing round to support the continued development of SonoThera’s ultrasound-guided, nonviral, gene therapy platform and treatments, designed to provide patients with genetic medicines.
ARCH Venture Partners led the Series A financing and was joined by investors Illumina Ventures, Johnson & Johnson Innovation – JJDC, Inc., Vertex Ventures HC, and Medical Excellence Capital. Also participating in the financing were Eli Lilly & Company, Alexandria Venture Investments, Lifespan Investments, Formic Ventures and Foothill Ventures.
SonoThera, Inc. is a biotechnology company dedicated to treating the root cause of human disease through genetic therapy. SonoThera is developing an ultrasound-guided, nonviral gene therapy platform and treatments designed to provide patients with the next generation of safe and effective genetic medicines. The platform utilizes sonoporation, a microbubble-mediated biophysical process to non-invasively deliver genetic payloads selectively targeting a wide range of organs within the body.
The Goodwin team was led by Yasin Akbari, Patrick O’Brien and Kingsley Taft, and included Tim Ayotte and Kathy Georgian (Corporate), Alan Wang, Noelle Dubiansky, Beth Withers and Elliot Horlick (Licensing), Richard Matheny, Amy Josselyn and Gozde Guckaya (Global Trade), Jennifer Fay, Philip Baldwin (Labor and Employment) and Dan Karelitz (Tax).
For additional details on the financing, please read the press release.